Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon

Part of paid clinical trials in Encino, California.

Sponsor
Colvard Kandavel Eye Center
Study ID
NCT07268599
Status
Enrolling By Invitation

Conditions

  • Dry Eye Disease (DED)

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Acoltremon — DRUG
    Patients will administer Acoltremon 0.003% as per labeled directions. Assessments with the Ocular Surface Disease Index (OSDI) will occur at Baseline, treatment at 14 days, and treatment at 28 days. Secondary endpoints include change from baseline rating scale 1-5 in severity of various symptoms of dry eye: Blurriness, eye irritation/Discomfort, Burning/Stinging, Photophobia/Pain, Sandy/gritty/Foreign Body Sensation, Fatigue/Tired Eyes).

Study Details

To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS). The primary aim is to characterize the rapidity of symptomatic relief in moderate to severe dry eye disease (DED), with attention to short-term therapy.

Key Dates

Start date
Nov 24, 2025
Status verified
Dec 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Change from baseline in Ocular Surface Disease Index at 28 days [ Time Frame: Baseline and 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Colvard-Kandavel Eye CenterEncinoCalifornia91316-

Find similar trials in Encino, CA

By research site
Colvard-Kandavel Eye Center· Encino, CA

Related Studies